Inspira Technologies Awaits Final Approval for ART100 in UAE

Inspira Technologies Oxy BHN ( (IINN) ) has issued an update.

On November 6, 2025, Inspira Technologies announced the completion of its regulatory submission for the ART100 system to the UAE Ministry of Health and Prevention, with final approval expected soon. This milestone is part of Inspira’s strategy to expand in the Gulf region, leveraging the UAE’s efficient regulatory framework. The anticipated authorization is expected to enhance regional partnerships and unlock commercialization potential across the Middle East’s healthcare networks.

The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.

The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira is also developing the INSPIRA ART500 and the HYLA blood sensor platform. The company is positioned within the life-support and MedTech landscape, focusing on strategic partnerships and industry trends.

Average Trading Volume: 688,773

Technical Sentiment Signal: Strong Sell

Current Market Cap: $22.53M

Learn more about IINN stock on TipRanks’ Stock Analysis page.